Figure 6.

(I) (a) Fluorescence photos taken in vivo showing the thrombin activity before and after intravenous delivery of the non-targeted NPs or FITC-LASG-PEGylated Fe3O4 nanoprobe. Imaging of abdominal aorta and carotid artery in vivo using fluorescence (top row). (b) After the injection of either a non-targeted or FITC-LASG-PEGylated Fe₃O₄ nanoprobe, dynamic variations in fluorescence signal intensity were quantified. (c) Fluorescence and micro-CT scan pictures that have been combined (FITC-non-targeted peptide PEGylated Fe₃O₄ NPs as the non-targeted nanoprobe); (II) (a) Confocal microscopy images of carotid artery segment after injecting FITC-LASG- PEGylated-Fe3O4 nanoprobe. (b) Fluorescence imaging of extracted organs ex vivo 10 min and 6hour post injection (c) Prussian blue staining 1hour post-injection of excised organs. (d) ICP-MS analysis of urine samples collected post-injection and slices of excised organ tissue; (III) T2-weighted MRI of the carotid artery of mice undergoing thrombosis before to, immediately after, and 1 and 24 hours after nanoprobe or non-targeted NP administration. The location of arterial thrombi is shown by yellow arrows. Reproduced with permission from ref. 80. Fig. 5, Fig. 6, and Fig. 7 (ACS Publication).